Superworth

enGene Therapeutics EPS ENGN

Diluted earnings per share by quarter and over the last twelve months, from 2023.

Last 12 months, to Jul 31, 2026
−$1.20
Latest quarter, Q3 FY26
−$0.47
Fiscal year 2025
−$1.34
−263% on the year before

enGene Therapeutics' earnings per share was −$1.20 over the twelve months to Jul 31, 2026.

In its latest quarter, Q3 FY26, it was −$0.47.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$1.34−263%
FY2024$0.82n/a
FY2023−$86.81n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q3 FY26−$0.47n/a−$1.20
Q2 FY26−$0.43n/a−$1.30
Q1 FY26$0.44−8%−$1.38
Q4 FY25−$0.74n/a−$1.34
Q3 FY25−$0.57−278%−$0.94
Q2 FY25−$0.51−234%−$0.05
Q1 FY25$0.48+4%$0.84
Q4 FY24−$0.34n/a$0.82
Q3 FY24$0.32−96%−$116.79
Q2 FY24$0.38−96%−$108.56
Q1 FY24$0.46−97%−$99.64
Q4 FY23−$117.95n/a−$86.81

Against its peers

Companies in Healthcare nearest enGene Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
ENGNenGene Therapeutics−$1.20
KEQUKewaunee Scientific$2.76−33% a year
ICCCImmucell$0.08−58% a year
LFVNLifevantage$0.40−46% a year
SPROSpero Therapeutics$0.11
APTAlpha Pro Tech$0.41+24% a year
PDEXPro DEX$4.11+52% a year
PLXProtalix BioTherapeutics$0.23+283% a year
NATRNatures Sunshine Products$1.01+36% a year
ELMDElectromed$1.31+56% a year
ATNMActinium Pharmaceuticals$0.36
Peer median$0.41

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on enGene Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.